Vimarsana
Biggest News Aggregation in the World

Page 12 - Greg Engel News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Greg Engel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Greg Engel Today - Breaking & Trending Today

Nextleaf Solutions Onboards New Partner and Delivers Initial Bulk CBD Order - Vimarsana News

Nextleaf Solutions Onboards New Partner and Delivers Initial Bulk CBD Order

Nextleaf Solutions Onboards New Partner and Delivers Initial Bulk CBD Order April 21 | 2021 Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) (“Nextleaf”, “OILS”, or the “Company”) , the world’s most innovative cannabis processor, is pleased to announce that its wholly-owned subsidiary Nextleaf Labs Ltd. (“Nextleaf Labs” or “Labs”) has completed an inaugural bulk CBD distillate delivery to a U.S.-listed, Canadian-based global cannabis company. The Company anticipates similar orders on an ongoing basis. Cann...

1 Top Canadian Pot Stock to Buy on Sale - Vimarsana News

1 Top Canadian Pot Stock to Buy on Sale

Image source: Getty Images Organigram Holdings (TSX:OGI)(NASDAQ:OGI) is a top Canadian pot stock that is currently trading at a discount. The company reported lower revenue in the second quarter, but sales are expected to improve in the third quarter. Organigram missed estimates in Q2 2021 Organigram posted second-quarter revenue below analyst expectations. The pot company’s net revenue was $14.6 million in the second quarter of 2021 compared to $23.2 million in the same quarter a year earlier. Organigram missed analysts’ estimates of $19.1 million. Q2 2021 net revenue...

Source: fool.ca
BLUMA WELLNESS INC by Bluma Wellness Inc. (BMWLF), JUSHI HLDGS INC CL B by Jushi Holdings Inc. (JUSHF), S&P Dep Receipts (SPY), Molson Coors Brewing Company (TAP) - The Week In Cannabis: New Mexico, Switzerland, Federal Legalization, Aphria, Organigram And More - Vimarsana News

BLUMA WELLNESS INC by Bluma Wellness Inc. (BMWLF), JUSHI HLDGS INC CL B by Jushi Holdings Inc. (JUSHF), S&P Dep Receipts (SPY), Molson Coors Brewing Company (TAP) - The Week In Cannabis: New Mexico, Switzerland, Federal Legalization, Aphria, Organigram And More

In spite of some good news on the legalization front, cannabis stocks traded down this week, largely driven by lackluster earnings reports out of big Canadian companies. On Monday, New Mexico became the latest state to legalize adult-use cannabis, after Gov. Michelle Lujan Grisham signed the Cannabis Regulation Act. Sales are expected to begin before April 2022. Following a legalization wave led by New York and Virginia, this approval puts more than 43% of Americans living in legal cannabis jurisdictions, according to The Marijuana Policy Project. Switzerland will officially launch a trial ve...

Organigram Posts Poor 2021 Second Quarter - Vimarsana News

Organigram Posts Poor 2021 Second Quarter

91.9 The Bend photo taken inside Organigram Organigram was heavily impacted by COVID-19 in their second fiscal quarter of 2021, recording a 37% drop in net revenue compared to the same period last year. The Moncton-based cannabis producer reported a net revenue of over $14.6 million on Tuesday morning. The company’s ability to meet demands was affected when an employee tested positive for the virus in a Moncton facility. As a result, staff had to isolate, and the grounds had to be disinfected, halting the production operations. In addition, a lower interest from wholesale buyers and a decis...

How Growing Number Of Clinical Trials Are Influencing Growth Of The Cannabis Pharmaceuticals - Vimarsana News

How Growing Number Of Clinical Trials Are Influencing Growth Of The Cannabis Pharmaceuticals

How Growing Number Of Clinical Trials Are Influencing Growth Of The Cannabis Pharmaceuticals News provided by Share this article Financialnewsmedia.com News Commentary PALM BEACH, Fla., April 14, 2021 /PRNewswire/ -- The medical cannabis market has made some remarkable accomplishments in the past few years with the launch of innovative products. The clinical trials and approval of some cannabis-infused products have opened up the market for cannabinoid-based pharmaceuticals. The market for cannabis pharmaceutical is still in the nascent phase with higher opportunities. The growing legalizatio...